Trade Filings
Managers Stocks Filings Superinvestors
Signals Institutional Buying Institutional Selling Insider Activity 13D & 13G Watch Sector Rotation
Tools Stock Screener Manager Screener Compare Managers Consensus Baskets All Research Tools Data API
Learn & AI Learn Ask the Data AI Agents
News ★ Saved
About About us Methodology Contact Disclaimer
Reader
DATA PLANS

Historical data downloads — coming with accounts.

API GATEWAY

Free read-only JSON access to the site's cached data.

Dark mode

🧭 Guided View
New to markets — prices, yields, YTD, market cap? We explain every term as you browse, in plain English. Same data, with the help built in.

⚡ Expert View
You already know the market. Just the data — clean, fast and compact, with no extra explanations. This is the default view.

Interface language
Security record · archived quarter

CGEM

Cullinan Therapeutics, Inc. · Healthcare · Biotechnology

22.85 -0.4% mkt cap $1.40B quote delayed (FMP) · as of Aug 26 21:08 UTC — separate from filing data below

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
10Tracked holders
+1Δ holders
6.86MShares held
$114.80MReported value
+1New positions
−0Exits
Rising Conviction score 42/100 How these are computed → Explain this at the Research Desk →

Momentum inputs (comparable managers): holder breadth +11.1% · share flow -3.7% · net new positions +10.0%formula
Ownership fragmentation — more holders, smaller aggregate stake

All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024

Ownership over time
QuarterHoldersΔSharesReported valueNewExits
Q2 2026 77 +7 28.05M $510.52M +11 −4
Q1 2026 73 +7 24.59M $348.81M +10 −3
Q4 2025 65 +1 21.69M $224.52M +1
Q3 2025 17 +1 15.39M $91.26M +1
Q2 2025 13 0 14.48M $109.06M +1 −1
Q1 2025 10 -1 7.69M $58.25M −1
Q4 2024 11 0 8.98M $109.41M
Q3 2024 10 +1 6.86M $114.80M +1
Q2 2024 9 7.12M $124.19M
Holder count
Who holds it · Q3 2024
#ManagerSharesΔ sharesValueTheir weightHeld
1 Citadel Advisors 1.96M +0.6% $32.73M 0.0% ▲ Add 2 SEC ↗
2 Adage Capital Partners 1.36M -39.3% $22.70M 0.0% ▼ Trim 2 SEC ↗
3 Geode Capital Management (passive) 1.21M +23.8% $20.23M 0.0% ▲ Add 2 SEC ↗
4 Geode Capital Management (passive) 1.21M +23.8% $20.23M 0.0% ▲ Add 2 SEC ↗
5 Marshall Wace 1.05M -11.0% $17.64M 0.0% ▼ Trim 2 SEC ↗
6 Millennium Management 788.57K New $13.20M 0.0% New 1 SEC ↗
7 Renaissance Technologies 281.80K -33.2% $4.72M 0.0% ▼ Trim 2 SEC ↗
8 Wellington Management 106.03K +47.1% $1.77M 0.0% ▲ Add 2 SEC ↗
9 Wellington Management 106.03K +47.1% $1.77M 0.0% ▲ Add 2 SEC ↗
10 D. E. Shaw & Co. 59.24K -72.1% $991,678 0.0% ▼ Trim 2 SEC ↗
11 T. Rowe Price 25.57K +22.9% $429,000 0.0% ▲ Add 2 SEC ↗
12 Two Sigma Investments 22.94K -60.0% $384,083 0.0% ▼ Trim 2 SEC ↗

“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.

New buyers

Millennium Management $13.20M 0.0%

Exited

No tracked exits this quarter.

Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 172 holders, 65.27M shares, $895.39M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.

Frequently co-owned

What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.

Insider transactions

Open-market purchases (P)

No open-market insider purchases in our coverage window.

Open-market sales (S)

Aug 13 Michaelson Jennifer

Officer · 30.00K sh · $607,800

Awards, exercises and tax withholding are never counted as buys or sales here. Methodology

Beneficial ownership
Aug 14 SC 13G/A — BIOTECHNOLOGY VALUE FUND L P

View original SEC filing ↗

Aug 14 SC 13G — PRICE T ROWE ASSOCIATES INC /MD/

View original SEC filing ↗

Aug 07 SC 13G — STATE STREET CORP

View original SEC filing ↗

Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR. Reporting period: Q3 2024 · Methodology · Get this via the API